Pharmaceutical

ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific

BMS paid $150m upfront to enter a collaborative development deal for bispecific IMA401 with Immatics in 2021.

Sep 18, 2024 - 04:00
ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific
BMS paid $150m upfront to enter a collaborative development deal for bispecific IMA401 with Immatics in 2021.
Read the original article

Tags:

Previous Article

Podcast: How drones are transforming the clinical supply chain in Africa

Next Article

FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

UK MHRA approves new formulation of Amgen’s XGEVA

UK MHRA approves new formulation of Amgen’s XGEVA

Mar 1, 2024

Kellogg’s is going to war over Mexico’s nutrition label rules. A similar fight is coming to the U.S.

Kellogg’s is going to war over Mexico’s nutrition label...

Aug 21, 2023

Lilly strikes deal with QurAlis for preclinical ALS candidate

Lilly strikes deal with QurAlis for preclinical ALS can...

Jun 4, 2024